CancerSELECT™ 125 analyzes the regions of a targeted panel of 125 well-characterized cancer genes. Matched tumor/normal or tumor samples are prepared using proprietary methods that accommodate low abundance, poor quality sample DNA. Combined with a proprietary capture design and high coverage next-generation sequencing, tumor-specific (somatic) mutations, copy number variations, microsatellite instability (MSI) and translocations are identified with a high sensitivity and specificity.
CancerSELECT™ 125 Sequencing Key Metrics | |
---|---|
Regions Analyzed | Coding regions of 117 genes and selected regions of 41 genes |
Sequencing Method | Illumina next generation sequencing |
Bioinformatics | Patented PARE, Digital Karyotyping and VariantDx |
Assay Sensitivity | >99% |
Assay Specificity | >99.9999% |
Sequencing Coverage | 1,250x |
Turn-around Time | 2-3 weeks |
Sample Requirements | Tumor only or tumor and matched normal (optimal results) |
Sample Types | Frozen tumor or FFPE, cell lines, blood, saliva, and xenograft |
DNA Input Required | 1μg (minimum 50ng) |
PlasmaSELECT™ 64 analyzes circulating tumor DNA for genetic alterations in cancer,eliminating the need for an invasive biopsy or tumor tissue. PlasmaSELECT™ 64 may also be used to evaluate subclonal mutations in tumor tissue, when available. PlasmaSELECT™ 64 evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations, rearrangements or microsatellite instability (MSI) can be performed together or separately, depending on the specific alterations of interest.
PlasmaSELECT™ 64 Key Metrics | |
---|---|
Regions Analyzed | 64 Genes |
Sequencing Method | Illumina next-generation sequencing |
Bioinformatics | Patented PARE, Digital Karyotyping and VariantDx |
Turn-around Time | 2-3 weeks |
Sample Requirements | Whole blood or plasma |
Sample Input Required | Two 10 ml tubes of peripheral whole blood; 6-10 ml plasma collected according to PGDx sample preparation instructions (>1-2ml for RUO) |